Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma

We investigated whether transfer of the gene encoding the angiogenesis inhibitor endostatin into the NIH/3T3 fibroblast cell line could inhibit renal tumor growth in vivo. NIH/3T3 cells were transduced with retroviral vectors containing the murine endostatin (ES) gene. SCID mice bearing CaKi-1 deriv...

Full description

Saved in:
Bibliographic Details
Published in:The FASEB journal 2007-10, Vol.21 (12), p.3153-3161
Main Authors: Coutinho, Enia Lúcia, de Sousa Andrade, Luciana Nogueira, Chammas, Roger, Morganti, Ligia, Schor, Nestor, Bellini, Maria Helena
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - metabolism
Animals
antiangiogen‐esis
Antineoplastic Agents - metabolism
Apoptosis - physiology
bioassay
cancer
Carcinoma, Renal Cell - metabolism
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - therapy
Cell Line, Tumor
Endostatins - genetics
Endostatins - metabolism
gene therapy
Gene Transfer Techniques
Humans
Male
Mice
Mice, SCID
Neoplasm Transplantation
NIH 3T3 Cells
Retroviridae - genetics
Retroviridae - metabolism
Transduction, Genetic
Transplantation, Heterologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated whether transfer of the gene encoding the angiogenesis inhibitor endostatin into the NIH/3T3 fibroblast cell line could inhibit renal tumor growth in vivo. NIH/3T3 cells were transduced with retroviral vectors containing the murine endostatin (ES) gene. SCID mice bearing CaKi-1 derived tumors were given a subcutaneous injection of either ES-transduced cells or control cells and were monitored for tumor growth. At the end of the in vivo experiment, the mean tumor volume of treated mice was 51.6 ± 2.4 mm³, while the tumor volume of control was 234.5 ± 14.8 mm³. Microvascular density was significantly decreased on treatment (control 9.79 vs. ES 2.53%,
ISSN:0892-6638
1530-6860
DOI:10.1096/fj.07-8412com